Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2009

Open Access 01-12-2009 | Research

Factors associated with seroprevalence of hepatitis C among dentists at a large Brazilian city

Authors: Vera Lúcia S Resende, Mauro Henrique G Abreu, Saul M Paiva, Rosângela Teixeira, Isabela A Pordeus

Published in: Virology Journal | Issue 1/2009

Login to get access

Abstract

Background

The aim of the present study was to investigate the seroprevalence and sociodemographic data, health-related and occupational factors and other correlates of sero-posivity among dentists in the city of Belo Horizonte, MG, Brazil.

Methods

A cross-sectional survey was carried out with 1302 dentists in Belo Horizonte, Brazil. All dentists were tested for anti-HCV using a commercially available enzyme-linked immunosorbent assay (ELISA). Individuals positive for anti-HCV were recalled for further evaluation. The presence of HCV RNA in anti-HCV-positive samples was assessed using reverse transcription-polymerase chain reaction (RT-PCR). Data on demographic, behavioural and occupational exposure aspects were collected through questionnaires.

Results

The seroprevalence of anti-HCV was 0.9% (95% IC 0.5-1.7%). The factors associated to the prevalence of hepatitis C were history of blood transfusion (p = 0.002) and having undergone a test for hepatitis C (p = 0.015).

Conclusions

The seroprevalence of anti-HCV among dentists is low. Moreover, no occupational exposure was associated to the seroprevalence of hepatitis C.
Literature
1.
Humphreys H, Smith ET: Prevalence surveys of healthcare-associated infections; what do they tell us, if anything? Clin Microbiol Infect 2006, 12: 2-4. 10.1111/j.1469-0691.2005.01273.xCrossRefPubMed
2.
Fitzpatrick F, McIlvenny G, Oza A, Newcombe RG, Humphreys H, Cunney R, Murphy N, Ruddy R, Reid G, Bailie R, Lavelle C, Doherty L, Smyth ET: Hospital infection society prevalence survey of Healthcare Associated Infection 2006: comparison of results between Northern Ireland and the Republic of Ireland. J Hosp Infect 2008, 69: 265-73. 10.1016/j.jhin.2008.04.016CrossRefPubMed
3.
Araujo MW, Andreana S: Risk and prevention of transmission of infectious diseases in dentistry. Quintessence Int 2002, 33: 376-82.PubMed
4.
CDC - Centers for Disease Control and Prevention: Transmission of Hepatitis B and C Viruses in Outpatient Settings - New York, Oklahoma, and Nebraska. MMWR 2003, 52: 901-6.
5.
Deisenhammer S, Radon K, Nowak K, Reichert J: Needlestick injuries during medical training. J Hosp Infect 2006, 63: 263-7. 10.1016/j.jhin.2006.01.019CrossRefPubMed
6.
Cleveland JL, Cardo DM: Occupational exposures to human immunodeficiency virus, hepatitis B virus, and hepatitis C virus: risk, prevention, and management. Dent Clin North Am 2003, 47: 681-96. 10.1016/S0011-8532(03)00041-7CrossRefPubMed
7.
Porter S, Scully C, Samaranayake L: Viral Hepatitis: Current concepts for dental practice. Oral Surg Oral Med Oral Pathol 1994, 78: 682-95. 10.1016/0030-4220(94)90082-5CrossRefPubMed
8.
Fry DE: Occupational blood-borne diseases in surgery. Am J Surg 2005, 190: 249-54. 10.1016/j.amjsurg.2005.05.021CrossRefPubMed
9.
10.
Henderson DK: Managing Occupational risks for hepatitis C transmission in the healthcare setting. Clin Microbiol Rev 2003, 16: 546-68. 10.1128/CMR.16.3.546-568.2003PubMedCentralCrossRefPubMed
11.
Alberti A, Benvegnù L, Boccato S, Ferrari A, Sebastiani G: Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004, 36: 646-54. 10.1016/j.dld.2004.06.011CrossRefPubMed
12.
Abou MA, Eltahir YM, Ali AS: Seroprevalence of Hepatitis B virus and Hepatitis C virus among blood donors in Nyala, South Dar Fur, Sudan. Virol J 2009, 6: 146. 10.1186/1743-422X-6-146PubMedCentralCrossRefPubMed
13.
Stroffolini T, Mariano A, Iantosca G: Reported risk factors are useless in detection HCV-positive subjects in the general population. Dig Liver Dis 2004, 36: 547-50. 10.1016/j.dld.2004.03.013CrossRefPubMed
14.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358: 958-65. 10.1016/S0140-6736(01)06102-5CrossRefPubMed
15.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975-82. 10.1056/NEJMoa020047CrossRefPubMed
16.
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha 2a ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346-65.CrossRefPubMed
17.
Wright M, Grieve R, Roberts J, Main J, Thomas HC: UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mil chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol Assess 2006, 10: 1-113.CrossRef
18.
Deutsch M, Hadziyannis SJ: Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 2008, 15: 2-11.PubMed
19.
Moloughney BW: Transmission and postexposure management of bloodborne virus infections in the healthcare setting: where are we now? CMAJ 2001, 165: 445-51.PubMedCentralPubMed
20.
Alter MJ: Prevention of spread of Hepatitis C. Hepatology 2002, 36: S93-S98. 10.1002/hep.1840360712CrossRefPubMed
21.
Shehab TM, Orrego M, Chunduri R, Lok AS: Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003, 98: 639-44. 10.1111/j.1572-0241.2003.07331.xCrossRefPubMed
22.
Ilgüy D, Ilgüy M, Semanur D, Bayirh G: Prevalence of the patients with history of hepatitis in a dental faculty. Med Oral Patol Oral Cir Bucal 2006, 11: E29-E32.PubMed
23.
Foccacia R, Conceicao OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, Lomar AV, Lorenço R, Vieira De Souza F, Kiffer CR, Santos EB, Gonzales MP, Sáez-Alquézar A, Riscal JR, Fischer D: Estimated prevalence of viral hepatitis in the general population of the municipality of Sao Paulo, measured by a serologic survey stratified, randomized and residence-based population. Braz J Infect Dis 1998, 2: 269-84.
24.
Ferrari JO, Ferreira UM, Tahnaka A, Mizokami M: The seroprevalence of hepatitis B and C in an Amerindian population in the southwestern Brazilian Amazon. Rev Soc Bras Med Tropical 1999, 32: 299-302.CrossRef
25.
Paltanin LF, Reiche EM: Seroprevalence of anti-hepatitis C virus antibodies among blood donors, Brazil. Rev Saude Publica 2002, 36: 393-9. 10.1590/S0034-89102002000400004CrossRefPubMed
26.
Oliveira MK, Bastos FI, Telles PR, Yoshida CF, Schatzmayr HG, Pauli G, Shreier E: Prevalence and risk factors for HBV, HCV and HDV infections among injection drug users from Rio de Janeiro, Brazil. Braz J Med Biol Res 1999, 32: 1107-14.PubMed
27.
Naghettini AV, Daher RR, Martin RM, Doles J, Vanderborght B, Yoshida CF, Rouzere C: Soroprevalencia do virus da hepatite C na populacao em dialise de Goiania, GO. Rev Soc Bras Med Tropical 1997, 30: 113-7.CrossRef
28.
Santana GO, Cotrim HP, Mota E, Paraná R, Santana NP, Lyra L: Anticorpo contra o vírus C da hepatite em pacientes sob programa de hemodiálise em Salvador, BA, Brasil. Arq Gastroenterol 2001, 38: 24-31. 10.1590/S0004-28032001000100006CrossRefPubMed
29.
Medeiros MT, Lima JM, Lima JW, Campos HH, Medeiros MM, Coelho-Filho JM: Prevalence and associated factors to hepatitis C in hemodialysis patients in Brazil. Rev Saude Publica 2004, 38: 187-93. 10.1590/S0034-89102004000200006CrossRefPubMed
30.
Mendes-Correa MC, Barone AA, Guastini C: Hepatitis C virus seroprevalence and risk factors among patients with HIV infection. Rev Inst Med Trop S Paulo 2001, 43: 15-9. 10.1590/S0036-46652001000100003CrossRefPubMed
31.
Burattini MN, Massad E, Rozman AR, Carvalho HB: Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica 2000, 34: 431-6. 10.1590/S0034-89102000000500001CrossRefPubMed
32.
Souto FJ, Silva AG, Yonamine F: Risk factors of hepatitis C among Brazilian ex-soccer players. Mem Inst Oswaldo Cruz 2003, 98: 1025-6. 10.1590/S0074-02762003000800008CrossRefPubMed
33.
Lodi G, Porter SR, Teo CG, Scully C: Prevalence of HCV infection in healthcare workers of UK dental hospital. Br Dent J 1997, 183: 329-32.CrossRefPubMed
34.
Nagao Y, Matsuoka H, Kawaguchi T, Ide T, Sata M: HBV and HCV infection in Japanese dental care workers. Int J Mol Med 2008, 21: 791-9.PubMed
35.
Bellíssimo-Rodrigues WT, Machado AA, Bellíssimo-Rodrigues F, Nascimento MP, Figueiredo JF: Prevalence of hepatitis B and C among Brazilian dentists. Infect Control Hosp Epidemiol 2006, 27: 887-8. 10.1086/506407CrossRefPubMed
36.
Takahama AJ, Tatsch F, Tannus G, Lopes MA: Hepatitis C: incidence and knowledge among Brazilian dentists. Community Dent Health 2005, 22: 184-7.PubMed
37.
Dean AG, Dean JA, Coulombier D, Burton AH, Brendei KA, Smith DC: Epi Info™, Version 6.04a, a word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta: Centers for Disease Control and Prevention; 1996.
38.
Streiner DL, Norman GL: Health measurements scales: a practical guide to their development and use. 2nd edition. Oxford: Oxford University; 2005.
39.
Machado-Carvalhais HP, Ramos-Jorge ML, Auad SM, Martins LH, Paiva SM, Pordeus IA: Occupational exposure to potentially infectious biological material in dental teaching environment. J Dent Educ 2008, 72: 1201-8.PubMed
40.
Sofola OO, Savage KO: Assessment of the compliance of Nigerian dentists with infection control: a preliminary study. Infec Cont Hosp Epidemiol 2003, 24: 737-40. 10.1086/502122CrossRef
41.
Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107CrossRefPubMed
42.
Pawlotsky JM: Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36: S65-S73. 10.1002/hep.1840360709CrossRefPubMed
43.
Colin C, Lanoir D, Touzet L, Meyaud-Kraemer F, Bailly F, Trepo C, the HEPATITIS Group: Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001, 8: 87-95. 10.1046/j.1365-2893.2001.00280.xCrossRefPubMed
44.
Weber C, Collet-Schaub D, Fried R, Lambrecht JT, Erb P, Meyer J: Low prevalence of hepatitis C virus antibody among Swiss dental healthcare workers. J Hepatology 2001, 34: 963-4. 10.1016/S0168-8278(01)00032-0CrossRef
45.
Gerberding JL: Incidence and prevalence of human immunodeficiencyvirus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among healthcare personel at ris for bllod exposure: final report from a longitudinal study. J Infect Dis 1994, 170: 1410-7.CrossRefPubMed
46.
Allain JP, Stramer SL, Carneiro-Proietti AB, Martins ML, Lopes da Silva SN, Ribeiro M, Proietti FA, Reesink HW: Transfusion-transmitted infectious diseases. Biologicals 2009, 37: 71-7. 10.1016/j.biologicals.2009.01.002CrossRefPubMed
47.
Stramer SL: Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007, 131: 702-7.PubMed
Metadata
Title
Factors associated with seroprevalence of hepatitis C among dentists at a large Brazilian city
Authors
Vera Lúcia S Resende
Mauro Henrique G Abreu
Saul M Paiva
Rosângela Teixeira
Isabela A Pordeus
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2009
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-6-228

Other articles of this Issue 1/2009

Virology Journal 1/2009 Go to the issue

Short report

Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study

Research

Comparative functional analysis of Jembrana disease virus Tat protein on lentivirus long terminal repeat promoters: evidence for flexibility at its N-terminus

Research

Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infection

Review

Feeling manipulated: cytomegalovirus immune manipulation

Research

Development of a fluorescent quantitative real-time polymerase chain reaction assay for the detection of Goose parvovirus in vivo

Research

Eukaryotic large nucleo-cytoplasmic DNA viruses: Clusters of orthologous genes and reconstruction of viral genome evolution
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits